The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone-Reference-Cited by-同舟云学术

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone

Published:2023-10-24 Issue:12 Volume:62 Page:1673-1693
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Heinig Roland^ORCID,Eissing Thomas^ORCID

Funder

This work was funded by Bayer AG, Wuppertal, Germany.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-023-01312-9.pdf

Reference52 articles.

1. Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol. 2017;243:271–305. https://doi.org/10.1007/164_2016_76.

2. Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237(4812):268–75. https://doi.org/10.1126/science.3037703.

3. Kolkhof P, Baerfacker L. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234(1):T125–40. https://doi.org/10.1530/JOE-16-0600.

4. Georgianos PI, Agarwal R. The non-steroidal MRA finerenone in cardiorenal medicine: a state-of-the-art review of the literature. Am J Hypertens. 2022;2:135–43. https://doi.org/10.1093/ajh/hpac124.

5. FDA. Integrated review Kerendia (finerenone). 2021. www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf. Accessed February 12, 2023.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of finerenone in individuals with type 2 diabetes mellitus complicated by diabetic kidney disease: A retrospective observational study;Metabolism Open;2024-12

2. Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease;Antioxidants;2024-06-03